In addition to 5‐ASA, biologics represented by anti‐TNF‐α are widely used in the treatment of IBD.[58] However, biologics cannot induce sustained remission and mucosal healing in all patients,[59] which may highlight the inadequacy of inhibiting inflammatory cytokines in the treatment of IBD. The gene discussed is TNF; the disease is inflammatory bowel disease.